Daniel Schneeberger, M.D.

Chief Executive Officer and Director

Daniel Schneeberger, M.D. joined our company as Chief Executive Officer and a member of our board of directors in July 2020. Dr. Schneeberger previously spent more than four years as an institutional investor in the biotechnology and healthcare sector, serving as Chief Executive Officer of ADAR1 Capital Management from January 2019 to June 2020, and senior analyst at JFL Capital Management LLC from May 2016 to December 2018, where he specialized in the prediction of clinical drug trial readouts as a basis for investments. Prior to his involvement with JFL Capital Management LLC, Dr. Schneeberger was a consultant at McKinsey & Company from April 2013 to May 2016. There, he advised clients in the pharmaceutical, private equity and agrochemical industry on research and development, portfolio decisions and commercial strategies. Dr. Schneeberger received his medical diploma and a doctorate in rheumatology from the University of Basel, Switzerland. He also earned an M.B.A. from Harvard Business School and was named a Baker Scholar.

Linda Klumpers, Ph.D.

Chief Scientific Officer

Dr. Klumpers earned her Masters in Neuroscience from the University of Amsterdam; then at Leiden University Medical Center (Leiden, Netherlands), earned a Clinical Pharmacology degree and a Ph.D. in Clinical Pharmacology of Cannabinoids. While in Leiden, she worked as a Clinical Scientist on a variety of clinical studies at the Centre for Human Drug Research. Dr. Klumpers has studied cannabinoids and cannabinoid antagonists in humans since 2006; she has co-authored several peer-reviewed cannabinoid publications including primary literature and book chapters. Her work has received acclaim such as the BJCP Prize, awarded by the British Journal of Clinical Pharmacology. In 2016 she started Cannify (https://www.cannify.us/), a website that provides general and customized cannabinoid education, to address the unmet need for objective cannabis information and education in the United States. In 2018 she and Dr. Michael Tagen formed Verdient Science (https://verdientscience.com/).

Rex Merchant

Chief Financial Officer

Rex Merchant joined our company as Chief Financial Officer in January 2021. He has served as the Chief Financial Officer of JFL Capital Management LLC since 2018 and of various other investment advisors and non-profit organizations since 1998. Prior to joining JFLCapital Management, Mr. Merchant served as Chief Financial Officer of Western Investment LLC, a hedge fund manager and investment advisory firm, from 2008 to 2017. Mr. Merchant also served as Chief Financial Officer of Leadership Foundations, a non-profit organization, from 2011 to 2018. He also has performed business valuation, litigation analysis and expert witness services, as well as extensive work in information technology throughout his career. Mr. Merchant received a B.S. degree in Industrial Engineering from Stanford University, and he holds Chartered Financial Analyst (CFA) and Chartered Alternative Investment Analyst (CAIA) designations.